A Phase Ib Dose Escalation Study of BCL201 in Combination With Idelalisib in Patients With Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

Trial Profile

A Phase Ib Dose Escalation Study of BCL201 in Combination With Idelalisib in Patients With Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Servier 1 (Primary) ; Idelalisib
  • Indications Follicular lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 30 Jun 2017 Planned End Date changed from 21 Jun 2019 to 22 Jun 2019.
    • 10 Jun 2017 Biomarkers information updated
    • 17 Mar 2017 Planned End Date changed from 18 Apr 2018 to 21 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top